Drug Profile
Tocilizumab biosimilar - AryoGen
Alternative Names: TEMZIVALatest Information Update: 09 Dec 2022
Price :
$50
*
At a glance
- Originator AryoGen Pharmed
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections; Rheumatoid arthritis
Most Recent Events
- 09 Dec 2022 Tocilizumab biosimilar is still in phase III development stage for COVID-2019 infections in Iran (IRCT20150303021315N17) (AryoGen pipeline, December 2022)
- 09 Dec 2022 Tocilizumab biosimilar is still in phase III development stage in Rheumatoid arthritis in Iran (SC) (IRCT20150303021315N9) (AryoGen pipeline, December 2022)
- 29 Nov 2022 Tocilizumab biosimilar is still in phase III trials for COVID-2019 infections in Iran (IRCT20150303021315N17)